191 reports of this reaction
3.4% of all CARVEDILOL PHOSPHATE reports
#4 most reported adverse reaction
DYSPNOEA is the #4 most commonly reported adverse reaction for CARVEDILOL PHOSPHATE, manufactured by Waylis Therapeutics LLC. There are 191 FDA adverse event reports linking CARVEDILOL PHOSPHATE to DYSPNOEA. This represents approximately 3.4% of all 5,587 adverse event reports for this drug.
Patients taking CARVEDILOL PHOSPHATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among CARVEDILOL PHOSPHATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for CARVEDILOL PHOSPHATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 191 FDA reports for CARVEDILOL PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.4% of all adverse event reports for CARVEDILOL PHOSPHATE, making it a notable side effect.
If you experience dyspnoea while taking CARVEDILOL PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.